Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides

Proteomics - Clinical Applications

Volumn 6, Issue 3-4, 2012, Pages 163-169

  Bibl, Mirko ^a   Gallus, Marion ^a   Welge, Volker ^a   Lehmann, Sabine ^a   Sparbier, Katrin ^b   Esselmann, Hermann ^a   Wiltfang, Jens ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b BRUKER DALTONIK GMBH   (Germany)

Author keywords

Alzheimer's dementia; Aminoterminally truncated; Cerebrospinal fluid; Electrophoresis; Oxidized amyloid peptides

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-37]; AMYLOID BETA PROTEIN[1-38]; AMYLOID BETA PROTEIN[1-39]; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[2-40]; AMYLOID BETA PROTEIN[2-42]; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PROTOCOL; CONTROLLED STUDY; HUMAN; IMMUNOBLOTTING; IMMUNOPRECIPITATION; PEPTIDE ANALYSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYNEUROPATHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN METABOLISM; PROTEIN MODIFICATION; PROTEOMICS; QUANTITATIVE ASSAY;

AGED; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; CROSS REACTIONS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MIDDLE AGED; OXIDATION-REDUCTION; PEPTIDE FRAGMENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84860347615     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100082     Document Type: Article

References (24)

1. Palmblad, M., Westlind-Danielsson, A., Bergquist, J., Oxidation of methionine 35 attenuates formation of amyloid β-peptide 1-40 oligomers. J. Biol. Chem. 2002, 277, 19506-19510.
2. Butterfield, D. A., Amyloid β-peptide (1-42)-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr. Med. Chem. 2003, 10, 2651-2659.
3. Johansson, A. S., Bergquist, J., Volbracht, C., Päiviö, A. et al., Attenuated amyloid-beta aggregation and neurotoxicity owing to methionine oxidation. Neuroreport 2007, 18, 559-563.
4. Misiti, F., Clementi, M. E., Giardina, B., Oxidation of methionine 35 reduces toxicity of the amyloid beta-peptide(1-42) in neuroblastoma cells (IMR-32) via enzyme methionine sulfoxide reductase A expression and function. Neurochem. Int. 2010, 56, 597-602.
5. Barnham, K. J., Ciccotosto, G. D., Tickler, A. K., Ali, F. E. et al., Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 2003, 278, 42959-42965.
6. Güntert, A., Döbeli, H., Bohrmann, B., High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience 2006, 143, 461-475.
7. Bibl, M., Mollenhauer, B., Esselmann, H., Lewczuk, P. et al., CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006, 129, 1177-1187.
8. Mollenhauer, B., Esselmann, H., Trenkwalder, C., Schulz-Schaeffer, W. et al., CSF amyloid-β peptides in neuropathologically diagnosed dementias with Lewy bodies and Alzheimer's disease. J. Alzheimers Dis. 2011, 24, 383-391.
9. World Medical Organisation, Declaration of Helsinki. Br. Med. J. 1996, 313, 1448-1449.
10. Wiltfang, J., Esselmann, H., Bibl, M., Smirnov, A. et al., Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and patients with chronic neuroinflammation. J. Neurochem. 2002, 81, 481-496.
11. Bibl, M., Esselmann, H., Otto, M., Lewczuk, P. et al., Cerebrospinal fluid (CSF) amyloid beta (Aβ) peptide patterns in Alzheimer's disease (AD) patients and non-demented controls depend on sample pre-treatment: indication of carrier-mediated epitope masking of Aβ peptides. Electrophoresis 2004, 25, 2912-2918.
12. Wiltfang, J., Smirnov, A., Schnierstein, B., Kelemen, G. et al., Improved electrophoretic separation and immunoblotting of beta-amyloid (Aβ) peptides 1-40, 1-42 and 1-43. Electrophoresis 1997, 18, 527-532.
13. Van Oostveen, I., Ducret, A., Aerbersold, R., Colloidal silver staining of electroblotted proteins for high sensitivity peptide mapping by liquid chromatography-electrospray ionization tandem mass spectrometry. Anal. Biochem. 1997, 247, 310-318.
14. Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M. et al., Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J. Biol. Chem. 2001, 276, 42645-42657.
15. Bibl, M., Mollenhauer, B., Lewczuk, P., Esselmann, H. et al., Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psy. 2007, 12, 671-680.
16. Lewczuk, P., Esselmann, H., Bibl, M., Paul, S. et al., Electrophoretic separation of amyloid β (Aβ) peptides in plasma. Electrophoresis. 2004, 25, 3336-3343.
17. Bibl, M., Esselmann, H., Mollenbauer, B., Wiltfang, J., Aminoterminally truncated and oxidized amyloid-beta peptide species in Alzheimer's disease. Neuroscience 2006, 143, 461-475.
18. Vanderstichele, H., De Meyer, G., Andreasen, N., Kostanjevecki, V. et al., Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment. Clin. Chem. 2005, 9, 1650-1660.
19. Albertini, V., Bruno, A., Paterlini, A., Lista, S. et al., Optimization protocol for amyloid-β peptides detection in human cerebrospinal fluid using SELDI TOF MS. Proteomics Clin. Appl. 2010, 3, 352-357.
20. Ghidoni, R., Paterlini, A., Albertini, V., Stoppani, E. et al., A window into the heterogeneity of human cerebrospinal fluid Aβ peptides. J. Biomed. Biotechnol. 2011, 2011, doi:10.1155/2011/697036.
21. Portelius, E., Westman-Brinkmalm, A., Zetterberg, H., Blennow, K., Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. J. Proteome. Res. 2006, 4, 1010-1016.
22. Portelius, E., Tran, A. J., Andreasson, U., Persson, R. et al., Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J. Proteome. Res. 2007, 11, 4433-4439.
23. Portelius, E., Brinkmalm, G., Tran, A. J., Zetterberg, H. et al., Identification of novel APP/Aβ isoforms in human cerebrospinal fluid. Neurodegener. Dis. 2009, 6, 87-94.
24. Ghidoni, R., Albertini, V., Squitti, R., Paterlini, A. et al., Novel T719P AbetaPP mutation unbalances the relative proportion of amyloid-beta peptides. J. Alzheimers. Dis. 2009, 2, 295-303.